Braakman E - Search Results

1

Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.

Gratama JW, Bruin RJ, Lamers CH, Oosterom R, Braakman E, Stoter G, Bolhuis RL. Gratama JW, et al. Among authors: braakman e. Clin Exp Immunol. 1993 May;92(2):185-93. doi: 10.1111/j.1365-2249.1993.tb03378.x. Clin Exp Immunol. 1993. PMID: 8485906 Free PMC article. Clinical Trial.

2

Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy.

Lamers CH, van de Griend RJ, Braakman E, Ronteltap CP, Bénard J, Stoter G, Gratama JW, Bolhuis RL. Lamers CH, et al. Among authors: braakman e. Int J Cancer. 1992 Jul 30;51(6):973-9. doi: 10.1002/ijc.2910510623. Int J Cancer. 1992. PMID: 1386349

3

T cell targeting in cancer therapy.

Bolhuis RL, Sturm E, Braakman E. Bolhuis RL, et al. Among authors: braakman e. Cancer Immunol Immunother. 1991;34(1):1-8. doi: 10.1007/BF01741317. Cancer Immunol Immunother. 1991. PMID: 1760806 Free PMC article. Review.

4

Expression of CD45 isoforms by fresh and activated human gamma delta T lymphocytes and natural killer cells.

Braakman E, Sturm E, Vijverberg K, van Krimpen BA, Gratama JW, Bolhuis RL. Braakman E, et al. Int Immunol. 1991 Jul;3(7):691-7. doi: 10.1093/intimm/3.7.691. Int Immunol. 1991. PMID: 1832950

5

Interleukin-2. The experience of the Rotterdam Cancer Institute; Daniel den Hoed Kliniek.

Stoter G, Goey SH, Eggermont AM, Slingerland R, Braakman E, Lamers C, Bolhuis RL. Stoter G, et al. Among authors: braakman e. Biotherapy. 1990;2(3):261-5. doi: 10.1007/BF02173527. Biotherapy. 1990. PMID: 2144993

6

Lymphocyte-mediated responses: activation of, and lysis by, cytotoxic lymphocytes.

Bolhuis RL, Braakman E. Bolhuis RL, et al. Among authors: braakman e. Curr Opin Immunol. 1988 Dec;1(2):236-40. doi: 10.1016/0952-7915(88)90007-6. Curr Opin Immunol. 1988. PMID: 3077307 Review. No abstract available.

7

CD16 on human gamma delta T lymphocytes: expression, function, and specificity for mouse IgG isotypes.

Braakman E, van de Winkel JG, van Krimpen BA, Jansze M, Bolhuis RL. Braakman E, et al. Cell Immunol. 1992 Aug;143(1):97-107. doi: 10.1016/0008-8749(92)90008-d. Cell Immunol. 1992. PMID: 1377991

8

Heterodimeric complex formation with CD8 and TCR by bispecific antibody sustains paracrine IL-2-dependent growth of CD3+ CD8+ T cells.

De Lau WB, Boom SE, Heije K, Griffioen AW, Braakman E, Bolhuis RL, Tax WJ, Clevers H, Bast BJ. De Lau WB, et al. Among authors: braakman e. J Immunol. 1992 Sep 15;149(6):1840-6. J Immunol. 1992. PMID: 1387662

9

Engineering T lymphocyte antigen specificity.

Bolhuis RL, Sturm E, Gratama JW, Braakman E. Bolhuis RL, et al. Among authors: braakman e. J Cell Biochem. 1991 Dec;47(4):306-10. doi: 10.1002/jcb.240470404. J Cell Biochem. 1991. PMID: 1724446 Review.

10

Genetic correction of cultured T cells from an adenosine deaminase-deficient patient: characteristics of non-transduced and transduced T cells.

Braakman E, Van Beusechem VW, Van Krimpen BA, Fischer A, Bolhuis RL, Valerio D. Braakman E, et al. Eur J Immunol. 1992 Jan;22(1):63-9. doi: 10.1002/eji.1830220111. Eur J Immunol. 1992. PMID: 1730260

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

75 results

Search Page

Filters